Calcitonin Gene-Related Peptide-targeted Therapies in Migraine: A Critical Appraisal of Current Evidence, Clinical Advances and Future Perspectives
Abstract
Migraine is among the leading causes of years lived with disability worldwide, yet for several decades its preventive pharmacology was borrowed from cardiology, epilepsy and psychiatry. Therapies directed at calcitonin gene-related peptide and its receptor constitute the first preventive class designed from migraine-specific biology, and eight agents belonging to two structural families, injectable monoclonal antibodies and small-molecule receptor antagonists known as gepants, are now in clinical use. This critical narrative review examines what the accumulated randomised, observational and pharmacovigilance evidence does and does not establish about this class in adults. Literature was identified through structured searching of biomedical and multidisciplinary scholarly databases and indexes, supplemented by backward and forward citation tracking and by examination of professional guidance, with a final search date of 15 July 2026. Studies were appraised for design adequacy, comparator choice, outcome definition, generalisability and consistency, and the evidence was organised thematically rather than study by study. Across pivotal trials the class produces reproducible but numerically modest reductions in monthly migraine days relative to placebo, typically between one and three days, while responder analyses and real-world cohorts identify a substantial subgroup deriving much larger benefit. The most defensible advantage over established oral preventive drugs lies in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.